By contrast, these tumor cells were insensitive to the type II FLT3 inhibitors quizartinib and sorafenib, which are known to be inactive in FLT3-TKD-mutated AML cells13 (Extended Data Fig. 5a,b). This evidence concerns the gene FLT3 and acute myeloid leukemia.